Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects

Gasdermin E suppresses tumour growth by activating anti-tumour immunity

(2020) Zhibin Zhang et al.   NATURE

Immunomodulation by targeted anticancer agents

(2020) Giulia Petroni et al.   CANCER CELL

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

(2020) Sonia Singh et al.   CLINICAL CANCER RESEARCH

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

(2019) Peng Liu et al.   Nature Communications

Immunosuppression by Mutated Calreticulin Released from Malignant Cells

(2019) Peng Liu et al.   MOLECULAR CELL

Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients

(2019) Lenka Kasikova et al.   Journal for ImmunoTherapy of Cancer

Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance

(2018) Zhenqing Ye et al.   CLINICAL CANCER RESEARCH

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

(2018) Samuel Y. Ng et al.   Nature Communications

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves

(2018) David P. Enot et al.   OncoImmunology

Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma

(2018) Matteo Menotti et al.   NATURE MEDICINE

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

(2017) Yvette L. Kasamon et al.   ONCOLOGIST

Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

(2017) Charlotte Rigaud et al.   PEDIATRIC BLOOD & CANCER

Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report

(2016) Holger Hebart et al.   ANNALS OF INTERNAL MEDICINE

The role of the ALK receptor in cancer biology

(2016) B. Hallberg et al.   ANNALS OF ONCOLOGY

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

(2016) J. Fucikova et al.   BLOOD

Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance

(2016) Federico Pietrocola et al.   CANCER CELL

Calreticulin Expression in Human Non–Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis

(2016) Jitka Fucikova et al.   CANCER RESEARCH

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK –Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls

(2016) Daniel Shao-Weng Tan et al.   Journal of Thoracic Oncology

Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation

(2016) Thomas Welte et al.   NATURE CELL BIOLOGY

Immunological off-target effects of imatinib

(2016) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity

(2016) Tania Løve Aaes et al.   Cell Reports

Innate Immune Recognition of Cancer

(2015) Seng-Ryong Woo et al.   Annual Review of Immunology

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

(2015) S. D. Bradley et al.   Cancer Immunology Research

High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors

(2014) Elisabet Aliagas et al.   MEDIATORS OF INFLAMMATION

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Consensus guidelines for the detection of immunogenic cell death

(2014) Oliver Kepp et al.   OncoImmunology

Autophagy-dependent ATP release from dying cells via lysosomal exocytosis

(2013) Yidan Wang et al.   Autophagy

Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors

(2013) S. Rusakiewicz et al.   CANCER RESEARCH

Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists

(2013) T Yamazaki et al.   CELL DEATH AND DIFFERENTIATION

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

(2013) Yuting Ma et al.   IMMUNITY

Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors

(2012) M. Ceccon et al.   MOLECULAR CANCER RESEARCH

Evolution of the cancer genome

(2012) Ondrej Podlaha et al.   TRENDS IN GENETICS

The immuno-oncology framework

(2012) Axel Hoos et al.   OncoImmunology

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

(2011) Nicolas F Delahaye et al.   NATURE MEDICINE

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk

(2010) K. Ait-Tahar et al.   BLOOD

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer

(2010) Rui-Qing Peng   WORLD JOURNAL OF GASTROENTEROLOGY

Immunogenic death of colon cancer cells treated with oxaliplatin

(2009) A Tesniere et al.   ONCOGENE

The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination

(2008) Roberto Chiarle et al.   NATURE MEDICINE